NASDAQ:AMPH

Amphastar Pharmaceuticals Competitors

$17.89
+0.11 (+0.62 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.66
Now: $17.89
$17.92
50-Day Range
$17.21
MA: $18.10
$19.36
52-Week Range
$15.50
Now: $17.89
$22.69
Volume96,000 shs
Average Volume199,584 shs
Market Capitalization$848.58 million
P/E Ratio127.79
Dividend YieldN/A
Beta0.87

Competitors

Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs. PTCT, APLS, INSM, ACAD, RETA, and KRTX

Should you be buying AMPH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Amphastar Pharmaceuticals, including PTC Therapeutics (PTCT), Apellis Pharmaceuticals (APLS), Insmed (INSM), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), and Karuna Therapeutics (KRTX).

Amphastar Pharmaceuticals (NASDAQ:AMPH) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 7.0% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amphastar Pharmaceuticals and PTC Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amphastar Pharmaceuticals03102.25
PTC Therapeutics05702.58

Amphastar Pharmaceuticals currently has a consensus target price of $21.6667, indicating a potential upside of 21.11%. PTC Therapeutics has a consensus target price of $64.90, indicating a potential upside of 36.34%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Amphastar Pharmaceuticals.

Profitability

This table compares Amphastar Pharmaceuticals and PTC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amphastar Pharmaceuticals1.97%5.50%4.04%
PTC Therapeutics-123.19%-76.10%-24.60%

Valuation and Earnings

This table compares Amphastar Pharmaceuticals and PTC Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amphastar Pharmaceuticals$322.36 million2.63$48.94 million$0.3649.69
PTC Therapeutics$306.98 million10.90$-251,580,000.00($3.45)-13.80

Amphastar Pharmaceuticals has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Summary

Amphastar Pharmaceuticals beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amphastar Pharmaceuticals and Apellis Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amphastar Pharmaceuticals03102.25
Apellis Pharmaceuticals031012.86

Amphastar Pharmaceuticals currently has a consensus target price of $21.6667, indicating a potential upside of 21.11%. Apellis Pharmaceuticals has a consensus target price of $124.6154, indicating a potential upside of 199.84%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Profitability

This table compares Amphastar Pharmaceuticals and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amphastar Pharmaceuticals1.97%5.50%4.04%
Apellis PharmaceuticalsN/A-336.93%-78.28%

Valuation and Earnings

This table compares Amphastar Pharmaceuticals and Apellis Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amphastar Pharmaceuticals$322.36 million2.63$48.94 million$0.3649.69
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-8.96

Amphastar Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Summary

Amphastar Pharmaceuticals beats Apellis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amphastar Pharmaceuticals and Insmed, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amphastar Pharmaceuticals03102.25
Insmed00703.00

Amphastar Pharmaceuticals currently has a consensus target price of $21.6667, indicating a potential upside of 21.11%. Insmed has a consensus target price of $53.8571, indicating a potential upside of 69.90%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Amphastar Pharmaceuticals.

Profitability

This table compares Amphastar Pharmaceuticals and Insmed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amphastar Pharmaceuticals1.97%5.50%4.04%
Insmed-145.14%-79.58%-31.14%

Valuation and Earnings

This table compares Amphastar Pharmaceuticals and Insmed's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amphastar Pharmaceuticals$322.36 million2.63$48.94 million$0.3649.69
Insmed$136.47 million23.99$-254,340,000.00($3.01)-10.53

Amphastar Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500.

Summary

Amphastar Pharmaceuticals beats Insmed on 9 of the 14 factors compared between the two stocks.

Amphastar Pharmaceuticals (NASDAQ:AMPH) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares Amphastar Pharmaceuticals and ACADIA Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amphastar Pharmaceuticals1.97%5.50%4.04%
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amphastar Pharmaceuticals and ACADIA Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amphastar Pharmaceuticals03102.25
ACADIA Pharmaceuticals012702.37

Amphastar Pharmaceuticals currently has a consensus target price of $21.6667, indicating a potential upside of 21.11%. ACADIA Pharmaceuticals has a consensus target price of $32.7647, indicating a potential upside of 60.69%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Insider & Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 27.7% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Amphastar Pharmaceuticals and ACADIA Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amphastar Pharmaceuticals$322.36 million2.63$48.94 million$0.3649.69
ACADIA Pharmaceuticals$339.08 million9.62$-235,260,000.00($1.60)-12.74

Amphastar Pharmaceuticals has higher earnings, but lower revenue than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Reata Pharmaceuticals (NASDAQ:RETA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Amphastar Pharmaceuticals and Reata Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amphastar Pharmaceuticals1.97%5.50%4.04%
Reata Pharmaceuticals-4,340.72%-163.42%-56.49%

Analyst Ratings

This is a summary of current ratings and target prices for Amphastar Pharmaceuticals and Reata Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amphastar Pharmaceuticals03102.25
Reata Pharmaceuticals00603.00

Amphastar Pharmaceuticals presently has a consensus price target of $21.6667, indicating a potential upside of 21.11%. Reata Pharmaceuticals has a consensus price target of $251.25, indicating a potential upside of 184.16%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reata Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Insider and Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 64.3% of Reata Pharmaceuticals shares are held by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 31.7% of Reata Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Amphastar Pharmaceuticals and Reata Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amphastar Pharmaceuticals$322.36 million2.63$48.94 million$0.3649.69
Reata Pharmaceuticals$26.52 million120.70$-290,170,000.00($9.54)-9.27

Amphastar Pharmaceuticals has higher revenue and earnings than Reata Pharmaceuticals. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Reata Pharmaceuticals has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Amphastar Pharmaceuticals and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amphastar Pharmaceuticals1.97%5.50%4.04%
Karuna TherapeuticsN/A-13.91%-13.72%

Analyst Ratings

This is a summary of current ratings and target prices for Amphastar Pharmaceuticals and Karuna Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amphastar Pharmaceuticals03102.25
Karuna Therapeutics001103.00

Amphastar Pharmaceuticals presently has a consensus price target of $21.6667, indicating a potential upside of 21.11%. Karuna Therapeutics has a consensus price target of $144.70, indicating a potential upside of 23.77%. Given Karuna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karuna Therapeutics is more favorable than Amphastar Pharmaceuticals.

Insider and Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are held by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 18.1% of Karuna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Amphastar Pharmaceuticals and Karuna Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amphastar Pharmaceuticals$322.36 million2.63$48.94 million$0.3649.69
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-31.77

Amphastar Pharmaceuticals has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.

Summary

Amphastar Pharmaceuticals beats Karuna Therapeutics on 8 of the 13 factors compared between the two stocks.


Amphastar Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60+1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56+0.0%$3.34 billionN/A-5.60
Insmed logo
INSM
Insmed
1.2$31.70+2.0%$3.27 billion$136.47 million-12.19
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39+1.4%$3.26 billion$339.08 million-11.85
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42+7.3%$3.20 billion$26.52 million-7.79
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91+0.9%$3.16 billionN/A-58.16
Arvinas logo
ARVN
Arvinas
1.5$63.49+1.5%$3.10 billion$42.98 million-24.80
Alkermes logo
ALKS
Alkermes
1.2$19.02+0.2%$3.03 billion$1.17 billion-41.35
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25+0.4%$2.99 billion$421.03 million24.03Analyst Report
Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.36+0.8%$2.94 billion$80.43 million106.48
Organogenesis logo
ORGO
Organogenesis
1.0$22.84+4.9%$2.92 billion$260.98 million-380.67
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18+2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83+0.2%$2.79 billion$644.77 million-10.39
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68+1.0%$2.66 billion$306.49 million25.48
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69+0.6%$2.56 billion$60,000.00-9.84
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77+13.2%$2.56 billionN/A0.00
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44+1.4%$2.55 billion$120.28 million-154.99
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77+1.1%$2.53 billion$2.11 million-8.82
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81+1.4%$2.52 billion$25 million-8.76
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41+8.7%$2.43 billionN/A-21.65
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19+0.9%$2.43 billion$182.24 million-7.99
Cryoport logo
CYRX
Cryoport
1.9$52.29+3.1%$2.38 billion$33.94 million-90.16Insider Selling
Xencor logo
XNCR
Xencor
1.2$40.47+2.9%$2.35 billion$156.70 million-28.91
Amarin logo
AMRN
Amarin
1.6$5.93+1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30+1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75+0.5%$2.18 billion$963.01 million13.59
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49+16.4%$2.10 billionN/A-29.14
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13+1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09+1.3%$1.99 billion$23.90 million-16.20Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99+2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43+3.8%$1.95 billion$103.54 million-19.12
MORF
Morphic
1.1$59.35+3.0%$1.93 billion$16.98 million-38.04Insider Selling
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57+0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58+0.1%$1.88 billion$34.51 million-17.59
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02+0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16+1.3%$1.87 billion$64.19 million-9.96
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96+2.7%$1.79 billion$1.63 billion14.54
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.2%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94+0.1%$1.77 billion$14.87 million-14.16
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93+21.0%$1.72 billionN/A0.00
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16+0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57+1.3%$1.70 billion$256.58 million-7.11High Trading Volume
Analyst Revision
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57+1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99+7.6%$1.65 billion$2.34 million-10.17
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15+1.2%$1.65 billionN/A-6.46
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26+6.0%$1.64 billionN/A0.00Insider Selling
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19+1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80+1.3%$1.63 billion$320,000.00-8.71Analyst Report
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32+0.2%$1.61 billionN/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.